Neurosciences

Overview

The Neuroscience area is consolidating its position as one of the largest clusters of research labs working on neurological diseases across Europe. Thirteen groups are currently part of this area, working closely with top clinicians at the hospital. The area encompasses different aspects related to neuroscience, such as neural development, neurodegeneration, neuroimmunology, neurological pain, mental health, neurosurgery, pediatric neurology or neuroimaging

There are groups also focused on cell signaling and apoptosis and translational bioinformatics.

Publications

242

total

1850.832

impact factor

7.648

average impact factor

Group Leader: Miquel Vila Bove

team

zoom

download

In 2018 we have developed a new therapeutic strategy to selectively decrease the brain levels of ?-synuclein in vivo selectively within monoaminergic neurons, the type of neurons most susceptible to neurodegeneration in Parkinson’s disease (PD). This technique is based on the intranasal administration of chemically-modified oligonucleotides. In addition, we have shown that PD-derived peripheral ?-synuclein aggregates are not pathogenic when injected into the brains of experimental animals. We have also described a neuroprotective role of transcription factor EB (TFEB) in a neurotoxic model of PD and demonstrated that the beneficial effect of TFEB goes beyond the activation of autophagy and implies a neurotrophic effect on dopaminergic neurons.

10

total

60^.384

impact factor

6^.038

average impact factor

SELECTED ARTICLES

Recasens A, Carballo-Carbajal I, Parent A, Bové J, Gelpi E, Tolosa E, Vila M.
Lack of pathogenic potential of peripheral ?-synuclein aggregates from Parkinson’s disease patients.
Acta Neuropathologica Communications (2018) 6(1):8
doi: 10.1186/s40478-018-0509-1
(IF: 5,414; Q1)
Alarcón-Arís D, Recasens A, Galofré M, Carballo-Carbajal I, Zacchi N, Ruiz-Bronchal E, Pavia-Collado R, Chica R, Ferrés-Coy A, Santos M, Revilla R, Montefeltro A, Fariñas I, Artigas F, Vila M*, Bortolozzi A*.
Selective alpha-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson disease.
Molecular Therapy (2018) 26(2):550-567) (*co-corresponding Authors)
doi: 10.1016/j.ymthe.2017.11.015.
(IF: 6,938; D1)
Torra A, Parent A, Cuadros T, Rodríguez-Galván B, Ruiz-Bronchal E, Ballabio A, Bortolozzi A, Vila M*, Bové J*.
Overexpression of TFEB drives a pleiotropic neurotrophic effect and prevents Parkinson’s disease-related neurodegeneration
Molecular Therapy (2018) 26(6):1552-1567 (*co-corresponding Authors)
doi: 10.1016/j.ymthe.2018.02.022
(IF: 6,938; D1)
Franco-Iborra S, Cuadros T, Parent A, Romero-Gimenez J, Vila M*, Perier C*.
Defective mitochondrial protein import contributes to complex I-induced mitochondrial dysfunction and neurodegeneration in Parkinson’s disease.
Cell Death & Disease (2018) 9(11):1122 (*co-corresponding Authors)
doi: 10.1038/s41419-018-1154-0
(IF: 5,638; Q1)
Lassot I, Mora S, Lesage S, Zieba B, Coque E, Condroyer C, Bossowski JP, Mojsa B, Marelli C, Tesson C, Carballo-Carbajal I, Laguna A, Mangone G, Vila M, Brice A, Desagher S.
The E3 ubiquitin-ligases TRIM17 and TRIM41 modulate ?-synuclein expression by regulating ZSCAN21.
Cell Reports (2018) 25(9):2484-2496.e9
doi: 10.1016/j.celrep.2018.11.002
(IF: 8.932; Q1)v

View all publications

Neurosciences

Overview

Publications

Group Leader: Miquel Vila Bove

Research Areas